Emphasis on Clinical Data Presented on DARZALEX™ (daratumumab) and IMBRUVICA® (ibrutinib) at the American Society of Hematology (ASH) in December 2015
NEW BRUNSWICK, N.J., Jan. 15, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and Johnson & Johnson JNJ will provide a pre-recorded webcast focused on data from the Janssen Oncology hematologic malignancy portfolio for investors and other interested parties on Friday, January 15.
The pre-recorded webcast features Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head of Oncology for Janssen R&D, recapping key data presentations on DARZALEX™ (daratumumab) and IMBRUVICA® (ibrutinib) that were featured at the 2015 American Society of Hematology (ASH) Annual meeting. Dr. Lebowitz will also describe the development plans for these and other compounds in the Janssen Oncology hematologic malignancy portfolio.
The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations." The webcast duration is approximately 18 minutes and will be available through the end of February.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/janssen-and-johnson--johnson-to-provide-webcast-presentation-on-the-janssen-oncology-hematologic-malignancy-portfolio-300205095.html
SOURCE Johnson & Johnson
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.